Media Contact

    • 04 December 2018
    • Rosen Comments on Report That Found Flaws in FDA Drug Approval Process

    • Partner David Rosen was quoted in a Modern Healthcare article, "Federal investigation finds holes in orphan drug approval process," about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration's process for approving so-called orphan drugs.
    • 19 November 2018
    • Faget Comments on FDA Proposal to Streamline Premarket Review Submissions

    • Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review.
    • 18 October 2018
    • Beaver Comments on FDA Guidance Over Recalls

    • Partner Nathan Beaver was quoted in an Inside Health Policy article, "Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls," about the FDA's recent guidance on disclosing food retailer information during certain recalls.
    • 25 July 2018
    • Rosen Comments on FDA Plan to Facilitate Biosimilars

    • Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
    • 15 May 2018
    • Rosen Comments on Proposed Changes in FDA Drug-Device Rules

    • Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
    • 05 April 2018
    • Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions

    • Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions.
    • 29 December 2017
    • Beaver Addresses FDA’s Planned New Guidance for Drug Developers

    • Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.
    Filters applied:
    Search phrase entered: